Inhalers Clinical Trial Analysis

Summary

Global Markets Direct's "Inhalers Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Inhalers manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Inhalers market categories - Dry Powder Inhaler Devices,Metered Dose Inhaler Devices
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Inhalers market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Inhalers Clinical Trials
  • 2.1 Inhalers Clinical Trial By Equipment Type
  • 2.2 Inhalers Clinical Trials By Trial Phase and Trial Status
  • 2.3 Inhalers Pipeline Products By Development Stage
  • 2.4 Inhalers Pipeline Products By Therapy Area
  • 2.5 Inhalers Pipeline Products By News Summary
  • 2.6 Inhalers Budesonide Clickhaler
    • 2.6.1 Efficacy And Tolerability Of Budesonide Clickhaler And Turbuhaler In Adult Asthma
    • 2.6.2 Assessment Of Adrenal Suppression From Two New Dry Powder Inhaler Formulations Of Budesonide Delivered By Clickhaler Compared With The Pulmicort Turbuhaler
    • 2.6.3 Gamma Scintigraphic Evaluation Of A Novel Budesonide Dry Powder Inhaler Using A Validated Radiolabeling Technique
    • 2.6.4 Bioavailability Of The Budesonide Delivered By The Clickhaler And Turbuhaler Dry Powder Inhalers In Healthy Volunteers: A Pilot Study
  • 2.7 Inhalers Staccato system-Disposable Single Dose
    • 2.7.1 Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of Staccato Zaleplon For Inhalation In Healthy Volunteers
    • 2.7.2 Tolerability, Safety And Pharmacokinetics Of A Single Dose Of Staccato Prochlorperazine For Inhalation In Normal, Healthy Volunteers
    • 2.7.3 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Patients With Bipolar I Disorder And Acute Agitation
    • 2.7.4 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Schizophrenic Patients With Agitation
    • 2.7.5 Abuse Liability Study Of Staccato Alprazolam For Inhalation In Subjects With Histories Of Sedative Abuse
    • 2.7.6 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy And Safety Outpatient Study Of Staccato Prochlorperazine For Inhalation In Patients With Migraine Headache
    • 2.7.7 Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of StaccatoM Alprazolam For Inhalation In Normal, Healthy Volunteers
    • 2.7.8 Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of Staccato Loxapine For Inhalation In Normal, Healthy Volunteers
    • 2.7.9 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy And Safety Study Of Staccato Prochlorperazine For Inhalation In Patients With Migraine Headache
    • 2.7.10 Investigation Of A Single Dose Of Staccato Alprazolam For Inhalation On Doxapram-Induced Panic Attack In Patients With Panic Disorder
    • 2.7.11 Thorough QT/QTc Study Of Staccato Prochlorperazine for Inhalation In Healthy Volunteers
    • 2.7.12 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Patients With Migraine Headache
    • 2.7.13 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Schizophrenic Patients With Agitation
  • 2.8 Inhalers Staccato system-Multiple Dose
    • 2.8.1 Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Staccato Loxapine For Inhalation In Subjects On Chronic, Stable Antipsychotic Regimens
    • 2.8.2 Safety, Tolerability, And Pharmacokinetics Of Staccato Fentanyl For Inhalation In Normal, Healthy Volunteers
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Jun 08, 2009: MannKind Initiates Development Of Next-Generation Inhalation System To Enhance Delivery Of Drug Powders
    • 3.1.2 Jan 15, 2009: Teva Specialty Pharmaceuticals Donates ProAir HFA To Direct Relief International Help Economically Disadvantaged Asthma Sufferers Breathe Easier
    • 3.1.3 Dec 10, 2008: 3M Licenses Dry Powder Inhaler Technology From Cambridge Consultants
    • 3.1.4 Nov 13, 2008: Delsite Presents Nasal Powder And Synthetic Typhoid Vaccine Technologies At The 2nd Vaccines Asia Conference
    • 3.1.5 Aug 13, 2008: Delsite Biotechnologies Nasal Powder Vaccine Platform Highlighted At Cambridge Healthtech Institute
    • 3.1.6 Aug 07, 2008: Avita Signs Greek Distribution Deal
    • 3.1.7 Oct 24, 2007: Bang & Olufsen Medicom Presents Positive Data For Inhalers
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Inhalers Clinical Trial By Equipment Type
  • Table 2: Inhalers Clinical Trials By Trial Phase and Trial Status
  • Table 3: Inhalers Pipeline Products By Development Stage
  • Table 4: Inhalers Pipeline Products By Therapy Area
  • Table 5: Inhalers Pipeline Products By News Summary
  • Table 6: Budesonide Clickhaler - Efficacy And Tolerability Of Budesonide Clickhaler And Turbuhaler In Adult Asthma
  • Table 7: Budesonide Clickhaler - Assessment Of Adrenal Suppression From Two New Dry Powder Inhaler Formulations Of Budesonide Delivered By Clickhaler Compared With The Pulmicort Turbuhaler
  • Table 8: Budesonide Clickhaler - Gamma Scintigraphic Evaluation Of A Novel Budesonide Dry Powder Inhaler Using A Validated Radiolabeling Technique
  • Table 9: Budesonide Clickhaler - Bioavailability Of The Budesonide Delivered By The Clickhaler And Turbuhaler Dry Powder Inhalers In Healthy Volunteers: A Pilot Study
  • Table 10: Staccato system-Disposable Single Dose - Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of Staccato Zaleplon For Inhalation In Healthy Volunteers
  • Table 11: Staccato system-Disposable Single Dose - Tolerability, Safety And Pharmacokinetics Of A Single Dose Of Staccato Prochlorperazine For Inhalation In Normal, Healthy Volunteers
  • Table 12: Staccato system-Disposable Single Dose - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Patients With Bipolar I Disorder And Acute Agitation
  • Table 13: Staccato system-Disposable Single Dose - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Schizophrenic Patients With Agitation
  • Table 14: Staccato system-Disposable Single Dose - Abuse Liability Study Of Staccato Alprazolam For Inhalation In Subjects With Histories Of Sedative Abuse
  • Table 15: Staccato system-Disposable Single Dose - Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of StaccatoM Alprazolam For Inhalation In Normal, Healthy Volunteers
  • Table 16: Staccato system-Disposable Single Dose - Safety, Tolerability, And Pharmacokinetics Of A Single Dose Of Staccato Loxapine For Inhalation In Normal, Healthy Volunteers
  • Table 17: Staccato system-Disposable Single Dose - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy And Safety Study Of Staccato Prochlorperazine For Inhalation In Patients With Migraine Headache
  • Table 18: Staccato system-Disposable Single Dose - Investigation Of A Single Dose Of Staccato Alprazolam For Inhalation On Doxapram-Induced Panic Attack In Patients With Panic Disorder
  • Table 19: Staccato system-Disposable Single Dose - Thorough QT/QTc Study Of Staccato Prochlorperazine for Inhalation In Healthy Volunteers
  • Table 20: Staccato system-Disposable Single Dose - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Patients With Migraine Headache
  • Table 21: Staccato system-Disposable Single Dose - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy And Safety Study Of Staccato Loxapine For Inhalation In Schizophrenic Patients With Agitation
  • Table 22: Staccato system-Multiple Dose - Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Staccato Loxapine For Inhalation In Subjects On Chronic, Stable Antipsychotic Regimens
  • Table 23: Staccato system-Multiple Dose - Safety, Tolerability, And Pharmacokinetics Of Staccato Fentanyl For Inhalation In Normal, Healthy Volunteers
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology